Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Starpharma in Nanotechnology (SPHRY) -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (4)	10/4/2008 4:40:14 PM
From: expatmike	Read Replies (2) \| Respond to of 9

R u still holding your 1000 shares of this stock? This company is hands down the most exciting and potentially $$$ cheap stock out there.. Dendrimers are nanotechnolog based, disrutptive technology that will change the face of pharmaceuticals. This is already becoming evident with this latest NR re to Durex condom coating, eh? This is only the beginning.. They are also developing thier niche in siRNA.. an extremely lucrative field of protien therepeutics -there are many more, multiple lucrative deals in the future! Starpharma Holdings (30 cents) has secured its most important commercial agreement to date, signing an exclusive licensing deal with the maker of the Durex condom, SSL International Plc. The agreement covers the use of Starpharma's microbicide, Vivagel, in SSL's condoms worldwide. The product is expected to be on the market within 18 months and to deliver Starpharma over $100 million in milestone payments and royalties. What is incredibly appealing about the Vivagel product is that there are no effective microbicides available on the market and very few in development. Nonoxinol-9 (N-9), which was previously used, has in fact been found to increase the probability of sexually transmitted diseases. Starpharma's Vivagel works not only as a spermicide, as did N-9, but also very effective at killing viruses such as HIV and HSV-2 (herpes virus). Spermicides have previously been incorporated into around 30%-40% of condoms on the market and SSL commands around 30% of the global branded condom market. The estimate of future income for Starpharma is spread over the life of the company's patents– roughly the next 15 years – however, this figure assumes SSL will not increase its current market share. There is the potential for the total future income stream to be considerably higher if the product is well accepted by consumers. Condoms with an effective microbicide can also command a 50% pricing premium. Ex-vivo trials will be conducted and it is expected that a small human safety study will be needed before the product gets to market. Both companies will be involved in final product development and regulatory submissions. Manufacturing of the active ingredient will be conducted by third parties on behalf of SSL. Future milestones will be payable on regulatory submission of the product, regulatory approval, and the achievement of sales targets. According to Starpharma's CEO, Dr Jackie Fairley, SSL is extremely excited by this product and the concept of a condom with virocide properties has also received very positive feedback from consumers. Starpharma is also commercialising Vivagel as a standalone product to prevent the transmission of sexually transmitted diseases, such as HIV and herpes, to be sold both in developing countries and in major western markets such as the US. These programs are being funded by the NIH grants of US$26 million. The company has a collaborative deal with another unnamed condom manufacturer for developing countries outside of the regions covered in the SSL deal. Starpharma is capitalised $54 million with $7.5 million in cash at mid year. This cash balance should increase with the receipt this quarter of an upfront payment from SSL. The company generated $9.9 million in the last financial year from government grants and royalty and licensing revenue.